The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.

Berneis, K., Rizzo, M. (2004). LDL size: does it matter ?. SWISS MEDICAL WEEKLY, 134(49-50), 720-724.

LDL size: does it matter ?

RIZZO, Manfredi
2004-01-01

Abstract

The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.
2004
Berneis, K., Rizzo, M. (2004). LDL size: does it matter ?. SWISS MEDICAL WEEKLY, 134(49-50), 720-724.
File in questo prodotto:
File Dimensione Formato  
16 SMW 2004.pdf

accesso aperto

Dimensione 133.6 kB
Formato Adobe PDF
133.6 kB Adobe PDF Visualizza/Apri
rizzo2004.pdf

accesso aperto

Dimensione 213.63 kB
Formato Adobe PDF
213.63 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/77808
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 33
social impact